Lenka Gibalová
About
In The Last Decade
Lenka Gibalová
12 papers receiving 378 citations
Peers
Comparison fields: 5 of 66
- Molecular Biology 233
- Oncology 200
- Cancer Research 49
- Epidemiology 39
- Infectious Diseases 30
Countries citing papers authored by Lenka Gibalová
This map shows the geographic impact of Lenka Gibalová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lenka Gibalová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lenka Gibalová more than expected).
Fields of papers citing papers by Lenka Gibalová
This network shows the impact of papers produced by Lenka Gibalová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lenka Gibalová. The network helps show where Lenka Gibalová may publish in the future.
Co-authorship network of co-authors of Lenka Gibalová
This figure shows the co-authorship network connecting the top 25 collaborators of Lenka Gibalová. A scholar is included among the top collaborators of Lenka Gibalová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lenka Gibalová. Lenka Gibalová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Title | Journal | Authors | Indexed citations |
|---|---|---|---|---|
| 1 | Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome. | PubMed | Anna Jonášová, Miroslav Barančı́k et al. | 4 |
| 2 | P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation | Toxicology in Vitro | Lenka Gibalová, Mário Šereš et al. | 50 |
| 3 | New Insight into P-Glycoprotein as a Drug Target | Anti-Cancer Agents in Medicinal Chemistry | Albert Breier, Lenka Gibalová et al. | 14 |
| 4 | New Insight into P-Glycoprotein as a Drug Target | Anti-Cancer Agents in Medicinal Chemistry | Albert Breier, Lenka Gibalová et al. | 7 |
| 5 | New Insight into P-Glycoprotein as a Drug Target | Anti-Cancer Agents in Medicinal Chemistry | Albert Breier, Lenka Gibalová et al. | 143 |
| 6 | Potentiation of Anticancer Drugs: Effects of Pentoxifylline on Neoplastic Cells | International Journal of Molecular Sciences | Miroslav Barančı́k, Lenka Gibalová et al. | 29 |
| 7 | The presence of P-glycoprotein in L1210 cells directly induces down-regulation of cell surface saccharide targets of concanavalin A. | PubMed | Zdena Sulová, Peter Ditte et al. | 28 |
| 8 | Multidrug resistant P-glycoprotein positive L1210/VCR cells are also cross-resistant to cisplatin via a mechanism distinct from P-glycoprotein-mediated drug efflux activity | General Physiology and Biophysics | Lenka Gibalová, J Sedlák et al. | 14 |
| 9 | Does any relationship exist between P-glycoprotein-mediated multidrug resistance and intracellular calcium homeostasis. | PubMed | Zdena Sulová, Mário Šereš et al. | 38 |
| 10 | Vincristine-Induced Overexpression of P-Glycoprotein in L1210 Cells Is Associated with Remodeling of Cell Surface Saccharides | Journal of Proteome Research | Zdena Sulová, Danica Mislovičová et al. | 22 |
| 11 | Structural differences between sensitive and resistant L1210 cells. | PubMed | B Uhrík, Lenka Gibalová et al. | 6 |
| 12 | Expression of P-glycoprotein in L1210 cells is linked with rise in sensitivity to Ca2+ | Biochemical and Biophysical Research Communications | Zdena Sulová, Ima Dovinová et al. | 24 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.